{"id":54825,"date":"2023-03-14T17:04:59","date_gmt":"2023-03-14T16:04:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/"},"modified":"2023-03-14T17:04:59","modified_gmt":"2023-03-14T16:04:59","slug":"cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/","title":{"rendered":"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations"},"content":{"rendered":"
\n

\nHaynes\u2019 global ophthalmology leadership to grow clinical operations at CXLO<\/i>\n<\/p>\n

SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics<\/a>, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations.\n<\/p>\n

<\/a><\/p>\n

\nWith more than 25 years of experience in ophthalmology, Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision. There, she was responsible for worldwide clinical training and competency on ophthalmic medical devices, managing more than 50 clinical trainers globally. Prior to Johnson & Johnson Vision, she served in progressive leadership roles at VISX, Advanced Medical Optics, and Abbott. Haynes was previously Director of two open-access laser centers in the Southeastern US.\n<\/p>\n

\n\u201cTiffany brings strong global medical affairs, ophthalmology management, regulatory and clinical trial experience to the CXLO team,\u201d commented Michael D. Webb, President and Chief Executive Officer of CXL Ophthalmics. \u201cAs the CXLO team advances clinical trials of our minimally-invasive EpiSmart program, we will benefit greatly from Tiffany\u2019s expertise.\u201d\n<\/p>\n

\n\u201cI am excited to join the dynamic team at CXLO to help improve safety and clinical outcomes for millions of patients at risk for vision loss due to keratoconus globally,\u201d said Haynes. \u201cI look forward to working with the CXLO team to develop accessible, patient-centered treatments that can be implemented upon diagnosis to prevent vision loss for patients with keratoconus.\u201d\n<\/p>\n

\nAbout CXL Ophthalmics<\/b>\n<\/p>\n

\nCXLO is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.\n<\/p>\n

\nFor more information, please visit www.cxlophthalmics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Tara Mulloy
\n
MacDougall Advisors<\/a>
(978) 855-5219
\n
tmulloy@macdougall.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Haynes\u2019 global ophthalmology leadership to grow clinical operations at CXLO SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Haynes previously served as Global Director, Medical Affairs … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54825","6":"format-standard","7":"category-industry"},"yoast_head":"\nCXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Haynes\u2019 global ophthalmology leadership to grow clinical operations at CXLO SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Haynes previously served as Global Director, Medical Affairs ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T16:04:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230314005793\/en\/1738124\/21\/CXLOpthalmics_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations\",\"datePublished\":\"2023-03-14T16:04:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005793\\\/en\\\/1738124\\\/21\\\/CXLOpthalmics_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/\",\"name\":\"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005793\\\/en\\\/1738124\\\/21\\\/CXLOpthalmics_logo.jpg\",\"datePublished\":\"2023-03-14T16:04:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005793\\\/en\\\/1738124\\\/21\\\/CXLOpthalmics_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005793\\\/en\\\/1738124\\\/21\\\/CXLOpthalmics_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/","og_locale":"en_US","og_type":"article","og_title":"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Pharma Trend","og_description":"Haynes\u2019 global ophthalmology leadership to grow clinical operations at CXLO SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Haynes previously served as Global Director, Medical Affairs ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-14T16:04:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230314005793\/en\/1738124\/21\/CXLOpthalmics_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations","datePublished":"2023-03-14T16:04:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/"},"wordCount":299,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005793\/en\/1738124\/21\/CXLOpthalmics_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/","url":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/","name":"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005793\/en\/1738124\/21\/CXLOpthalmics_logo.jpg","datePublished":"2023-03-14T16:04:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230314005793\/en\/1738124\/21\/CXLOpthalmics_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230314005793\/en\/1738124\/21\/CXLOpthalmics_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54825"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54825\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}